Patients with clinically suspected MEN1 had significantly higher rates of comorbidities, including diabetes, hypertension, dyslipidemia, cardiovascular disease, and osteoporotic fractures, compared to controls. This evidence concerns the gene MEN1 and metabolic syndrome.